Supplementary materials for manuscript
Metabolic features of the tumor microenvironment of gastric cancer
and the link to the systemic macroenvironment
Check list
Text S-1 The inclusion or exclusion criteria of the clinical patients in this study
Table S-1 The information of the volunteer patients
Table S-2 The low-molecular-weight compounds identified in gastric cancer tissue
and blood plasma
Figure S-1
a:
General clustering of tissue and plasma samples of GC and CSG
A PCA scores plot gives an overview of the data set and shows complete
separation of tissue samples(■) and plasma samples(□).
b:
A supervised PLS-DA scores plot shows better the clustering of different
groups.
Figure S-2
A 3-dimensional PLS-DA scores plot of the GC plasma, post-operation
GC plasma and the CSG controls plasma.
1
Text S-1 The inclusion or exclusion criteria of the clinical patients in this study
The inclusion or exclusion of the patients in the study was assessed based on the
data available.
Inclusion criteria included:
(1) aged between 30 and 60, both male or female;
(2) definite diagnosis pathologically and gastroscopically;
(3) the post-operation GC patients were performed surgery operation for at least 4
weeks, but not exceed 6 weeks.
Exclusion criteria were:
(1) metabolic disease, such as hyperlipoidemia, diabetes mellitus, gout;
(2) pregnant of lactating female;
(3) any symptom of acute disease during the last 2 weeks, such as: febrile, cough,
headache, diarrhoea, hematuria;
(4) momentous stress reaction during the last 2 weeks, such as psychic trauma and a
large area of empyrosis;
(5) hematopathy, including all types of leukemia and anaemia;
(6) use of specific drugs during the last 2 weeks, such as antibiotic (quinolones,
torlamician),
hormone
(deoxycortisone,
dexamethasone),
nonsteroid
anti-inflammatory drugs (NSAIDs; acenterine, saridon, contac), among others;
(7) medical treatments before blood collection, such as radiotherapy, chemotherapy.
2
Table S-1 The information of the volunteer patients
Characteristic
CSG
GC
GC_p
Male
11
12
9
Female
9
5
6
37.1±12.2
41.3±15.1
42.9±12.6
25-56
22-58
25-60
Drinking﹡
－
－
－
Smoking
－
－
－
Taking medicine*
－
－
－
H.pylori infection
+
+
+
Gender
Age(years)
Mean±SD
Range
*not during the last week
3
Table S-1 The low-molecular-weight compounds identified in gastric cancer tissue
and blood plasma
Identified compounds
Derivatives
Retention Index
Alanine
N-Acetylglutamate
2-Aminoadipate
Aminomalonate
2-Amino-phosphorate
Arachidonic acid
Ascorbic acid
Aspartate
Aspartate
Butyamine
Cholesterol
Citrate
Creatinine
Cysteine
Cystine
Decanoic acid
2,5-Diaminovalerolactam
2,6-Dihydroxy-9H-purine
Docosahexaenoic acid
Fructose-6-phosphate
Fumarate
N-formyl-Glycine
Galactofuranose-6-phosphate
D-Galactono-1,4-lactone
Glucose
Glucose, pentakis
Glutamate
Glutamine
Glutamine
Glutamine
Glycerate
Glycerol-3-phosphate
Glycine
Heptanoic acid
Hexadecanoic acid
9-(Z)-Hexadecenoic acid
-Hydroxybutyrate
Hypoxanthine
1H-Indole-3-propanoic acid
Lactate
Lactose
Leucine
Linoleic acid
Lysine
Lysine
Lysine
N,O-2TMS
O-2TMS
N,O-3TMS
N,O-3TMS
N,O-4TMS
O-TMS
O-2TMS
N,O-3TMS
N,O-3TMS
N-2TMS
O-TMS
O-4TMS
N,O-3TMS
N,S,O-3TMS
N,O-4TMS
O-TMS
N-2TMS
N,O-3TMS
O-TMS
O-6TMS
O-2TMS
N,O-2TMS
O-7TMS
O-4TMS
MEOX, O-5TMS
O-5TMS
N,O-3TMS
N,O-4TMS
N,O-4TMS
N,O-3TMS
O-3TMS
O-4TMS
N,O-3TMS
O-TMS
O –TMS
O –TMS
O-2TMS
N,O-2TMS
N,O-2TMS
O-2TMS
MEOX, 8TMS
N,O-2TMS
O-TMS
N,O-3TMS
N,O-4TMS
N,O-3TMS
1127
1542
1731
1486
1805
2376
1876
1488
1544
1124
3188
1843
1570
1571
2322
1462
1468
2044
2567
2364
1356
1388
2618
1989
1927
2016
1634
1610
1755
1790
1347
1788
1320
1188
2048
2029
1180
1821
2099
1083
2764
1287
2217
1722
1942
2082
4
Malate
Maltose
Methionine
S-methyl-Cysteine
-D-Methylglucopyranoside
Monomethylphosphate
Myo-Inositol
Myo-Inositol-1-phosphate
1-Monopalmitin
1-monostearin
Oleic acid
Ornithine
Ornithine
Phenylalanine
Phosphate
Proline
Proline
Pyroglutamate
Ribose
Robitol
Serine
Stearic acid
Succinate
Sucrose
Taurine
Threonate
Threonine
Alpha-Tocopherol
gamma-Tocopherol
Tryptophan
Tyrosine
Uracil
Urate
Urea
Urea
Uridine
Valine
O-3TMS
MEOX, 8TMS
N,O-2TMS
N,O-2TMS
O-4TMS
O-2TMS
O-6TMS
O-7TMS
O-2TMS
O-2TMS
O-TMS
N,O-3TMS
N,O-4TMS
N,O-2TMS
O-3TMS
N,O-2TMS
N,O-2TMS
O-2TMS
MEOX,O-4TMS
O-4TMS
N,O-3TMS
O-TMS
O-2TMS
O-8TMS
N,O-3TMS
O-4TMS
N,O-3TMS
O-TMS
O-TMS
N,O-3TMS
N,O-3TMS
O-2TMS
N,O-4TMS
N-3TMS
N-2TMS
O-3TMS
N,O-2TMS
1503
2817
1531
1434
2067
1199
2129
2471
2601
2795
2222
1629
1838
1641
1295
1309
1594
1534
1707
1739
1377
2246
1324
2708
1687
1584
1403
3162
3017
2245
1960
1351
2131
1202
1275
2480
1233
Altogether, 79 compounds were identified. Compounds are identified as TMS,
trimethylsilylated, and MEOX, methoxymated derivatives. Identification was
confirmed by comparing the mass spectra and retention indices with the authentic
references standards and those available in the National Institute of Standards and
Technology (NIST) library 2.0 (2005), an in-house mass spectra library database
established by the Umeå Plant Science Center(Umea, Sweden), and key lab of
drug metabolism and pharmacokinetics, China Pharmaceutical University.
5
Figure S-1
a:
General clustering of tissue and plasma samples
A PCA scores plot gives an overview of the data set and shows complete
separation of tissue samples(■) and plasma samples(□).
b:
A supervised PLS-DA scores plot shows better the clustering of different
groups.
6
Figure S-2
A 3-dimensional PLS-DA scores plot of the GC plasma, post-operation
GC plasma and the CSG controls plasma. Post-operation GC plasma showed
difference from GC plasma and was not overlapping with the CSG control, indicating
the metabolic phenotype of post-operation GC plasma did not restore completely.
7